Award of Share Options

RNS Number : 5338X

hVIVO plc

13 August 2018

 

hVIVO PLC

("hVIVO" or the "Company")

 

Award of Share Options

London, UK, 13 August 2018: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, announces that on 10 August 2018 it awarded the following options over ordinary shares of 5.0p each in the Company to Graham Yeatman:

Name	Position	Number of Share Options Awarded	Exercise price per Share	Date of Vesting	Percentage of issued ordinary share capital
Graham Yeatman	Chief Financial & Business Officer	100,000	5.0p	10 August 2021	0.1%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Graham Yeatman
2	Reason for the notification
a)	Position/ status	Chief Financial & Business Officer
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over Ordinary Shares of 5 pence each ISIN: GB00B6ZM0X53
b)	Nature of the transaction	Award of options over ordinary shares in the Company
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Exercise Price (p) Volume Graham Yeatman 5.0 100,000
e)	Aggregated information - Aggregated volume - Exercise price	Options over 100,000 ordinary shares 5.0p
f)	Date of the transaction	10 August 2018
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

hVIVO plc
Trevor Phillips (Executive Chairman)	[phone]
Fleur Wood (Director, Investor Relations)
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell	[phone]

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.

 

END

 

 

DSHURSBRWWAWAAR